Multiple studies have demonstrated that tumor enhancement on magnetic resonance imaging (MRI) is more prevalent in IDH1 wild-type gliomas compared to IDH1 mutant counterparts, with the degree of enhancement correlating with a relatively poorer prognosis [11,12,13]. This evidence concerns the gene IDH1 and central nervous system cancer.